Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Natural products are a diverse and interesting source for
2022-09-30

Natural products are a diverse and interesting source for the discovery of new lead structures (Newman and Cragg, 2016). After a successful era of natural product research, many pharmaceutical companies stopped their investment in natural product-driven drug discovery in the 1990s. The reason behind
-
Integrase inhibitors have been licensed
2022-09-29

Integrase inhibitors have been licensed for use in the UK since 2008. BHIVA now recommend starting all treatment naïve patients on a regimen containing two NRTIs, plus one of the following: a ritonavir boosted PI, an NNRTI, or an integrase inhibitor. They make further recommendations for patients wi
-
br Materials and methods br Results br
2022-09-29

Materials and methods Results Discussion Type I ECa is associated with estrogen excess, obesity and hormone-receptor positivity. However, the function of ERα on ECa is considered complicated. The expression of ERα is reduced in grade III ECa clinical samples [13]. The high ERα expression is
-
br Acknowledgement The work was supported by the
2022-09-29

6. Acknowledgement The work was supported by the NSFC through Grant Nos. 11535016 and 11475232. It was also supported by CAS. The authors thank their collaborators for beneficial discussions and enthusiastic supports in the simulations and calculations. Introduction Hypoxia-inducible factors
-
We previously evaluated the immuno modulatory
2022-09-29

We previously evaluated the immuno-modulatory efficacy of GSNO in different EAE models and reported prophylactic and therapeutic efficacy of GSNO against the clinical disease of EAE [22], [36]. GSNO inhibited the IL-6-induced STAT3 activation (Tyr705 phosphorylation) by S-nitrosylation of the STAT3
-
Lactate LA the end product
2022-09-29

Lactate (LA), the end product of aerobic glycolysis, has been long neglected and seen as a byproduct until recently the findings for its important role in global gene transcription, cancer progression, functional polarisation of immune GX-674 receptor and the sustenance of stem cells [[7], [8], [9]
-
Up to now many UDG assays have been reported based
2022-09-28

Up to now, many UDG assays have been reported based on the design of dU-containing substrate DNA, which can be roughly divided into two categories according to the sensing mechanisms. One type of UDG assays are simply based on the physical or chemical property changes of the substrate accompanied wi
-
br Regulation of Glu transporters The pivotal
2022-09-28

Regulation of Glu transporters The pivotal role of Glu transporters in the fine tuning and turnover of this excitatory amino adenylate cyclase calls for a detailed characterization of its regulation. Several general mechanisms that modify Glu uptake activity have been described. These include tr
-
The expression of GLUT receptors throughout the body could
2022-09-28

The expression of GLUT receptors throughout the body could be considered a potential source for off-target effects even for engineered glucose-conjugated nanomedicines, as there are at least 12 types of GLUT transporters in the body, including GLUT1 in erythrocytes and the blood-brain barrier, as we
-
The widespread involvement of HH GLI in human malignancies
2022-09-28

The widespread involvement of HH/GLI in human malignancies has initiated a remarkable effort to identify selective HPIs. As shown in Table 2.1, most of these small molecule inhibitors target the essential effector protein SMO, which should lead to pathway abrogation by eventually decreasing the GLIA
-
C527 australia Ulimorelin also known as TPZ is a macrocyclic
2022-09-28

Ulimorelin, also known as TPZ101, is a macrocyclic molecule that is a potent agonist of the ghrelin receptor (Hoveyda et al., 2011). Due to its ability to stimulate gastrointestinal motility, ulimorelin has been evaluated as a possible treatment in gastroparesis (Ejskjaer et al., 2010), ileus (Frase
-
br Summary br Conflict of interest br Acknowledgments This s
2022-09-27

Summary Conflict of interest Acknowledgments This study was supported by Grant No. 2014/13/B/NZ7/02277 from the National Science Centre, Poland. Introduction Progesterone (P) is an anticonvulsant hormone (Backstrom et al., 1984, Herzog, 1995, Herzog, 1999, Frye et al., 2000, Reddy, 2002
-
In summary the SAR of a series
2022-09-27

In summary, the SAR of a series of phenylpropanoic acid-free fatty Kaempferol receptor agonists is described which resulted in the identification of potent FFA4 agonists. The superior pharmacokinetic properties of compound led to its selection as an in vivo tool compound which afforded robust effica
-
Prion diseases are transmissible and result in fatal
2022-09-27

Prion diseases are transmissible and result in fatal neurodegenerative disorders, which, similar to AD, also involve the infiltration and activation of mononuclear phagocytes in cl pdx sale lesions (reviewed in [61]). A 21 amino-acid fragment of the aberrant human prion protein, Prp106–126, can form
-
Moreover long term treatment of leukemia
2022-09-24

Moreover, long term treatment of leukemia cells with imatinib activates AKT, ERK and STAT5 signaling pathway and induce upregulation of EZH2 protein in patients with CML, Ph + ALL and human eosinophilic leukemia cell line (EOL-1 cells) [142]. So, resistance to tyrosine kinase inhibitor (TKI) imatini
16057 records 403/1071 page Previous Next First page 上5页 401402403404405 下5页 Last page